TET2 and acute myeloid leukemia: Previous study has demonstrated that MEG3 gene expression is under epigenetic control, and aberrant CpG methylation occurs in AML patients.32 Downregulation of MEG3 in our TET2-mutant AML subtype samples implies that TET2 is likely to modulate MEG3 expression.